Monopar Therapeutics is recovering a drug from the scrap heap of AstraZeneca’s rare disease pipeline. | Monopar Therapeutics ...

Monopar Therapeutics (MNPR) announced that it has entered into an agreement with Alexion, AstraZeneca (AZN) Rare Disease for an exclusive ...

The company has made it easier to test for different protein modifications which are critical to the treatment of autoimmune ...

Monopar Therapeutics' market value nearly tripled Thursday after the biotechnology company agreed to license a treatment for patients with a rare genetic condition from AstraZeneca unit Alexion.

Under the terms of the license agreement, Monopar will pay Alexion an upfront in the form of a cash payment and equity in Monopar. Future payments are based on tiered royalties on net sales and ...

AstraZeneca, a global biopharmaceutical company that develops and commercializes prescription medicines, became a household ...

Sino-America clinical-stage biotech Eccogene announced that it will receive a $60 million payment from AstraZeneca, which is ...

AstraZeneca has rolled out a fresh TV spot for its blockbuster-to-be Breztri, hitting the me | AstraZeneca has rolled out a ...

Monopar Therapeutics shares rose after the biotechnology company agreed to license a treatment for patients with a rare genetic condition from AstraZeneca unit Alexion. Shares of the Wilmette, Ill., ...

AstraZeneca AZN and Ionis Pharmaceuticals IONS announced that the Committee for Medicinal Products for Human Use (CHMP) has ...

The big pharma company AstraZeneca has forged a licensing pact worth $2 billion with the Chinese firm CSPC Pharmaceutical ...

AstraZeneca and Ionis are collaborating on the commercialisation of the drug following a December 2021 global agreement.